These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

122 related items for PubMed ID: 19841438

  • 1. Summaries for patients. Effect of treatment with fluticasone with and without salmeterol on airway inflammation and lung function in patients with chronic obstructive pulmonary disease: a randomized trial.
    Ann Intern Med; 2009 Oct 20; 151(8):I21. PubMed ID: 19841438
    [No Abstract] [Full Text] [Related]

  • 2. Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial.
    Lapperre TS, Snoeck-Stroband JB, Gosman MM, Jansen DF, van Schadewijk A, Thiadens HA, Vonk JM, Boezen HM, Ten Hacken NH, Sont JK, Rabe KF, Kerstjens HA, Hiemstra PS, Timens W, Postma DS, Sterk PJ, Groningen Leiden Universities Corticosteroids in Obstructive Lung Disease Study Group.
    Ann Intern Med; 2009 Oct 20; 151(8):517-27. PubMed ID: 19841453
    [Abstract] [Full Text] [Related]

  • 3. Inhaled fluticasone and salmeterol suppress eosinophilic airway inflammation in chronic obstructive pulmonary disease: relations with lung function and bronchodilator reversibility.
    Perng DW, Wu CC, Su KC, Lee YC, Perng RP, Tao CW.
    Lung; 2006 Oct 20; 184(4):217-22. PubMed ID: 17006748
    [Abstract] [Full Text] [Related]

  • 4. TORCH study results: pharmacotherapy reduces lung function decline in patients with chronic obstructive pulmonary disease.
    McDonough C, Blanchard AR.
    Hosp Pract (1995); 2010 Apr 20; 38(2):92-3. PubMed ID: 20469618
    [No Abstract] [Full Text] [Related]

  • 5. Can inhaled fluticasone alone or in combination with salmeterol reduce systemic inflammation in chronic obstructive pulmonary disease? Study protocol for a randomized controlled trial [NCT00120978].
    Sin DD, Man SF, Marciniuk DD, Ford G, FitzGerald M, Wong E, York E, Mainra RR, Ramesh W, Melenka LS, Wilde E, Cowie RL, Williams D, Rousseau R, ABC (Advair, Biomarkers in COPD) Investigators.
    BMC Pulm Med; 2006 Feb 06; 6():3. PubMed ID: 16460562
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease.
    Vestbo J, Pauwels R, Anderson JA, Jones P, Calverley P, TRISTSAN study group.
    Thorax; 2005 Apr 06; 60(4):301-4. PubMed ID: 15790985
    [Abstract] [Full Text] [Related]

  • 11. Parasternal muscle activity decreases in severe COPD with salmeterol-fluticasone propionate.
    Easton PA, Hawes HG, Doig CJ, Johnson MW, Yokoba M, Wilde ER.
    Chest; 2010 Mar 06; 137(3):558-65. PubMed ID: 19820074
    [Abstract] [Full Text] [Related]

  • 12. [New studies refute steroid opponents. COPD--after all a case for corticosteroids?].
    Calverley P.
    MMW Fortschr Med; 2003 Jun 12; 145(24):20. PubMed ID: 12866294
    [No Abstract] [Full Text] [Related]

  • 13. Pharmacokinetics and pharmacodynamics of fluticasone propionate and salmeterol delivered as a combination dry powder from a capsule-based inhaler and a multidose inhaler in asthma and COPD patients.
    Daley-Yates PT, Mehta R, Chan RH, Despa SX, Louey MD.
    J Aerosol Med Pulm Drug Deliv; 2014 Aug 12; 27(4):279-89. PubMed ID: 24074143
    [Abstract] [Full Text] [Related]

  • 14. Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes.
    Anzueto A, Ferguson GT, Feldman G, Chinsky K, Seibert A, Emmett A, Knobil K, O'Dell D, Kalberg C, Crater G.
    COPD; 2009 Oct 12; 6(5):320-9. PubMed ID: 19863361
    [Abstract] [Full Text] [Related]

  • 15. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study.
    Celli BR, Thomas NE, Anderson JA, Ferguson GT, Jenkins CR, Jones PW, Vestbo J, Knobil K, Yates JC, Calverley PM.
    Am J Respir Crit Care Med; 2008 Aug 15; 178(4):332-8. PubMed ID: 18511702
    [Abstract] [Full Text] [Related]

  • 16. Differentiating asthma and COPD patients.
    El-Kassimi FA.
    Chest; 2004 Aug 15; 126(2):653-4; author reply 654-5. PubMed ID: 15302761
    [No Abstract] [Full Text] [Related]

  • 17. Additive effects of salmeterol and fluticasone or theophylline in COPD.
    Cazzola M, Di Lorenzo G, Di Perna F, Calderaro F, Testi R, Centanni S.
    Chest; 2000 Dec 15; 118(6):1576-81. PubMed ID: 11115442
    [Abstract] [Full Text] [Related]

  • 18. Influence of salmeterol/fluticasone via single versus separate inhalers on exacerbations in severe/very severe COPD.
    Hagedorn C, Kässner F, Banik N, Ntampakas P, Fielder K.
    Respir Med; 2013 Apr 15; 107(4):542-9. PubMed ID: 23337300
    [Abstract] [Full Text] [Related]

  • 19. Survival in COPD patients after regular use of fluticasone propionate and salmeterol.
    Marchand E.
    Eur Respir J; 2003 Mar 15; 21(3):559-60; author reply 560. PubMed ID: 12662020
    [No Abstract] [Full Text] [Related]

  • 20. Withdrawal of inhaled glucocorticoids and exacerbations of COPD.
    Magnussen H, Disse B, Rodriguez-Roisin R, Kirsten A, Watz H, Tetzlaff K, Towse L, Finnigan H, Dahl R, Decramer M, Chanez P, Wouters EF, Calverley PM, WISDOM Investigators.
    N Engl J Med; 2014 Oct 02; 371(14):1285-94. PubMed ID: 25196117
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.